February 2016

People who are fit are more likely to survive their first heart attack, a new study reveals, adding that low fitness may pose a risk of death following a cardiac arrest.

Researchers at the Harvard University including an Indian-origin scientist have replicated a folding human brain in 3D, revealing for the first time a simple mechanical framework for how it folds.

A team of European scientists has developed a new method to detect human stem cells in a cell culture and preserve them in the laboratory.

Both too short and too long sleep durations in pregnancy are associated with extremes of gestational weight gain, says a new study.

Just two months of healthy living classes can significantly reduce the risk of common diabetes complications, including cardiovascular disease, stroke, limb amputation and microvascular complications, says a study.

As the Zika virus outbreak continues to spread reaching 24 countries in the Americas, the World Health Organisation (WHO) has called on governments in the Middle East to work together to keep the region protected.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in ACADIA’s New Drug Application (NDA) for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease.

Allergan plc  announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo βlactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae (CRE), for which there are currently very limited treatments, thus presenting a new treatment option for patients with MBL-producing pathogens. Under the terms of the agreement, Allergan will maintain commercialization rights in the U.S. and Canada and AstraZeneca will maintain commercialization rights in all other countries.

Dr. Reddy's Laboratories, announced  that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. ZEMBRACESymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.

The U.S. Food and Drug Administration  approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. Halaven is marketed by Eisai based in Woodcliff Lake, New Jersey.